J. Salvador

Cost minimization analysis of treatment with intravenous or subcutaneous trastuzumab in patients with HER2-positive breast cancer in Spain

Guillermo López-Vivanco, J. Salvador, R Diez et al. · Clinical & Translational Oncology · 2017 · 50 citations · Full text

Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer

Magdalena Ruiz, J. Salvador, Juan L. Bayo et al. · Cancer Chemotherapy and Pharmacology · 2008 · 30 citations

Weekly Schedule, Breast Oncology, Oncology +5

Trajectories of alcohol consumption during life and the risk of developing breast cancer

Carolina Donat‐Vargas, Ángel Guerrero‐Zotano, Ana Casas et al. · British Journal of Cancer · 2021 · 30 citations · Full text

Bone turnover markers as predictive indicators of outcome in patients with breast cancer and bone metastases treated with bisphosphonates: Results from a 2-year multicentre observational study (ZOMAR study)

Agustí Barnadas, Luís Manso, Concepción de la Piedra et al. · Bone · 2014 · 18 citations · Full text

Bone Turnover Markers, Breast Oncology, Bone Health +9

Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions

J. Salvador, J. Aparicio Urtasun, F. J. B. Duart et al. · Clinical & Translational Oncology · 2016 · 15 citations · Full text